{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T01:02:55Z","timestamp":1784768575169,"version":"3.55.0"},"reference-count":17,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["mol clin onc"],"DOI":"10.3892\/mco.2019.1857","type":"journal-article","created":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T08:49:41Z","timestamp":1557478181000},"source":"Crossref","is-referenced-by-count":10,"title":["Neurokinin\u20111 receptor antagonist aprepitant and radiotherapy, a successful combination therapy in a patient with lung cancer: A case report"],"prefix":"10.3892","author":[{"given":"Miguel","family":"Mu\ufffdoz","sequence":"first","affiliation":[{"name":"Research Laboratory on Neuropeptides (IBIS), Virgen del Roc\ufffdo University Hospital, 41013 Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Crespo","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Pediatric and Radiology, University of Sevilla, 41009 Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\ufffd","family":"Crespo","sequence":"additional","affiliation":[{"name":"SEVISTON Laboratory Pathology, 41001 Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Cove\ufffdas","sequence":"additional","affiliation":[{"name":"Institute of Neurosciences of Castilla y Le\ufffdn (INCYL), Laboratory of Neuroanatomy of the Peptidergic Systems (Lab. 14), University of Salamanca, 37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2019,5,10]]},"reference":[{"key":"key20200713202430_b1-mco-0-0-1857","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2016","volume":"68","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"key20200713202430_b2-mco-0-0-1857","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1097\/JTO.0b013e318287c562","article-title":"Review of ongoing clinical trials in non-small-cell lung cancer: A status report for 2012 from the clinicaltrials.gov web site","volume":"8","author":"Subramanian","year":"2013","journal-title":"J Thorac Oncol"},{"key":"key20200713202430_b3-mco-0-0-1857","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1378\/chest.07-2680","article-title":"Targeting growth factors in lung cancer","volume":"133","author":"Hodkinson","year":"2008","journal-title":"Chest"},{"key":"key20200713202430_b4-mco-0-0-1857","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.peptides.2013.07.024","article-title":"Involvement of substance P and the NK-1 receptor in cancer progression","volume":"48","author":"Mu\u00f1oz","year":"2013","journal-title":"Peptides"},{"key":"key20200713202430_b5-mco-0-0-1857","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.peptides.2012.09.024","article-title":"The substance P\/neurokinin-1 receptor system in lung cancer: Focus on the antitumor action of neurokinin-1 receptor antagonists","volume":"38","author":"Mu\u00f1oz","year":"2012","journal-title":"Peptides"},{"key":"key20200713202430_b6-mco-0-0-1857","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.2174\/1570180814666170327163854","article-title":"Neurokinin-1 receptor antagonists in lung cancer therapy","volume":"14","author":"Mu\u00f1oz","year":"2017","journal-title":"Lett Drug Des Discov"},{"key":"key20200713202430_b7-mco-0-0-1857","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1126\/science.281.5383.1640","article-title":"Distinct mechanism for antidepressant activity by blockade of central substance P receptors","volume":"281","author":"Kramer","year":"1998","journal-title":"Science"},{"key":"key20200713202430_b8-mco-0-0-1857","doi-asserted-by":"publisher","first-page":"e24180","DOI":"10.1371\/journal.pone.0024180","article-title":"A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults","volume":"6","author":"Tebas","year":"2011","journal-title":"PLoS One"},{"key":"key20200713202430_b9-mco-0-0-1857","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1517\/14740338.2013.804059","article-title":"Safety of neurokinin-1 receptor antagonists","volume":"12","author":"Mu\u00f1oz","year":"2013","journal-title":"Expert Opin Drugs Safety"},{"key":"key20200713202430_b10-mco-0-0-1857","first-page":"105","article-title":"Antitumoural action of L-733,060 on neuroblastoma and glioma cell lines","volume":"142","author":"Mu\u00f1oz","year":"2004","journal-title":"Arch Ital Biol"},{"key":"key20200713202430_b11-mco-0-0-1857","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.npep.2005.03.004","article-title":"The NK1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on neuroblastoma and glioma cell lines","volume":"39","author":"Mu\u00f1oz","year":"2005","journal-title":"Neuropeptides"},{"key":"key20200713202430_b12-mco-0-0-1857","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jtho.2016.04.014","article-title":"PD-L1 Expression in lung cancer","volume":"11","author":"Yu","year":"2016","journal-title":"J Thorac Oncol"},{"key":"key20200713202430_b13-mco-0-0-1857","doi-asserted-by":"publisher","first-page":"071","DOI":"10.23937\/2378-3419\/3\/6\/1071","article-title":"Prolonged use of aprepitant in metastatic breast cancer and a reduction in CA153 tumour marker levels","volume":"3","author":"Lee","year":"2016","journal-title":"Int J Cancer Clin Res"},{"key":"key20200713202430_b14-mco-0-0-1857","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"key20200713202430_b15-mco-0-0-1857","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/0304-3940(94)91017-0","article-title":"Substance P receptors on human astro-cytoma cells are linked to glycogen breakdown","volume":"167","author":"Medrano","year":"1994","journal-title":"Neurosci Lett"},{"key":"key20200713202430_b16-mco-0-0-1857","first-page":"61","article-title":"Efectos de los antagonistas de los receptores NK1 y de la dexametasona sobre la inflamaci\u00f3n neurog\u00e9nica inducida por ciclofosfamida y por radiaci\u00f3n X, en la rata","volume":"23","author":"Alfieri","year":"2004","journal-title":"Archivos Venezolanos de Farmacologia y Terapeutica"},{"key":"key20200713202430_b17-mco-0-0-1857","doi-asserted-by":"publisher","first-page":"504","DOI":"10.6004\/jnccn.2017.0050","article-title":"Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"Ettinger","year":"2017","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"deposited":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T19:24:36Z","timestamp":1594668276000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mco.2019.1857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,10]]},"references-count":17,"URL":"https:\/\/doi.org\/10.3892\/mco.2019.1857","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,10]]}}}